N Vetter

2.4k total citations
42 papers, 1.4k citations indexed

About

N Vetter is a scholar working on Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, N Vetter has authored 42 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 12 papers in Infectious Diseases and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in N Vetter's work include Pneumonia and Respiratory Infections (9 papers), HIV/AIDS drug development and treatment (8 papers) and HIV Research and Treatment (7 papers). N Vetter is often cited by papers focused on Pneumonia and Respiratory Infections (9 papers), HIV/AIDS drug development and treatment (8 papers) and HIV Research and Treatment (7 papers). N Vetter collaborates with scholars based in Austria, United Kingdom and Germany. N Vetter's co-authors include Jens Lundgren, Amanda Mocroft, Christine Armbruster, Ole Kirk, Nelson L. Michael, Hermann Katinger, Gabriela Stiegler, Brigitta Vcelar, Walter Jäger and George Panos and has published in prestigious journals such as The Lancet, Cancer and Journal of Clinical Microbiology.

In The Last Decade

N Vetter

38 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N Vetter Austria 18 624 514 435 250 216 42 1.4k
Powel Kazanjian United States 27 1.0k 1.6× 267 0.5× 1.1k 2.4× 177 0.7× 46 0.2× 64 1.9k
Renato Maserati Italy 26 979 1.6× 727 1.4× 380 0.9× 124 0.5× 68 0.3× 104 1.7k
Sylvie Abel Martinique 25 1.1k 1.7× 794 1.5× 473 1.1× 196 0.8× 153 0.7× 62 2.0k
William P. Bradley United States 22 400 0.6× 167 0.3× 459 1.1× 241 1.0× 70 0.3× 47 1.3k
Raquel Martínez Switzerland 23 703 1.1× 668 1.3× 249 0.6× 412 1.6× 47 0.2× 40 1.5k
Henry C. Mwandumba United Kingdom 19 738 1.2× 141 0.3× 615 1.4× 227 0.9× 69 0.3× 77 1.3k
Vanni Borghi Italy 23 1.1k 1.7× 910 1.8× 557 1.3× 242 1.0× 55 0.3× 102 1.8k
Örjan Strannegård Sweden 23 404 0.6× 450 0.9× 407 0.9× 104 0.4× 139 0.6× 54 1.5k
Christophe Michon France 14 505 0.8× 246 0.5× 356 0.8× 244 1.0× 36 0.2× 32 1.1k
Allan R. Tenorio United States 22 1.0k 1.6× 1.1k 2.1× 424 1.0× 230 0.9× 64 0.3× 55 2.4k

Countries citing papers authored by N Vetter

Since Specialization
Citations

This map shows the geographic impact of N Vetter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Vetter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Vetter more than expected).

Fields of papers citing papers by N Vetter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N Vetter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Vetter. The network helps show where N Vetter may publish in the future.

Co-authorship network of co-authors of N Vetter

This figure shows the co-authorship network connecting the top 25 collaborators of N Vetter. A scholar is included among the top collaborators of N Vetter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N Vetter. N Vetter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mokoala, Kgomotso, et al.. (2025). Alternative treatment for recurrent keloids: initial clinical experience with Rhenium-188 using a specialized device. European Journal of Nuclear Medicine and Molecular Imaging. 52(9). 3151–3158.
2.
Aichelburg, A, Julia Walochnik, Ojan Assadian, et al.. (2008). Successful Treatment of DisseminatedAcanthamoebasp. Infection with Miltefosine. Emerging infectious diseases. 14(11). 1743–1746. 92 indexed citations
3.
Braun, Otto, Peter Dalquen, W. Popp, et al.. (2008). Immunzytochemische Untersuchungen in der Diagnostik der pulmonalen Histiocytosis X. DMW - Deutsche Medizinische Wochenschrift. 114(3). 91–95.
4.
Smith, Colette, Christian Holkmann Olsen, Amanda Mocroft, et al.. (2008). The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS. 22(1). 47–56. 32 indexed citations
5.
Mocroft, Amanda, Ole Kirk, Pauls Aldiņš, et al.. (2008). Loss to follow‐up in an international, multicentre observational study. HIV Medicine. 9(5). 261–269. 78 indexed citations
6.
Katlama, Christine, Roberto Esposito, José M. Gatell, et al.. (2007). Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 21(4). 395–402. 148 indexed citations
7.
Podlekareva, Daria, Amanda Mocroft, Ulrik Bak Dragsted, et al.. (2006). Factors Associated with the Development of Opportunistic Infections in HIV‐1–Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. The Journal of Infectious Diseases. 194(5). 633–641. 62 indexed citations
8.
Pohl, Wolfgang, et al.. (2005). Adjustable maintenance dosing with budesonide/formoterol or budesonide: Double-blind study. Respiratory Medicine. 100(3). 551–560. 17 indexed citations
9.
Armbruster, Christine, Gabriela Stiegler, Brigitta Vcelar, et al.. (2002). A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS. 16(2). 227–233. 108 indexed citations
10.
Viard, Jean‐Paul, Amanda Mocroft, Antonio Chiesi, et al.. (2001). Influence of Age on CD4 Cell Recovery in Human Immunodeficiency Virus–Infected Patients Receiving Highly Active Antiretroviral Therapy: Evidence from the EuroSIDA Study. The Journal of Infectious Diseases. 183(8). 1290–1294. 188 indexed citations
11.
Maesen, F. P. V., et al.. (1999). Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. Journal of Antimicrobial Chemotherapy. 43(4). 529–539. 68 indexed citations
12.
Ukena, D., Ulf Harnest, Raimundas Sakalauskas, et al.. (1997). Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. European Respiratory Journal. 10(12). 2754–2760. 109 indexed citations
13.
Vetter, N, David Stamler, Sean O’Neill, et al.. (1997). Clarithromycin vs Combined Cefuroxime and Erythromycin in the Treatment of Hospitalised Community-Acquired Pneumonia Patients - Intravenous Followed by Oral Therapy. Clinical Drug Investigation. 14(6). 439–449. 6 indexed citations
14.
Vetter, N. (1995). Phänomenologie und Postmoderne. 12(1-4). 34–42. 2 indexed citations
15.
Wettengel, R, et al.. (1993). Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis. Journal of Antimicrobial Chemotherapy. 31(6). 963–972. 15 indexed citations
16.
Mohn, Angelika, et al.. (1991). Induced sputum and cytological diagnosis of lung cancer. The Lancet. 338(8773). 976–977. 16 indexed citations
17.
Hutterer, J., Dietmar Fuchs, Gilbert Reibnegger, et al.. (1990). Neopterin Changes during Zidovudine Treatment of HIV-1 Infection. Pteridines. 2(2). 81–82. 1 indexed citations
18.
Burghuber, Otto C., et al.. (1990). Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer. 65(6). 1386–1390. 84 indexed citations
19.
Valdés, E. López, P Géhanno, Helen Giamarellou, et al.. (1989). Clinical experience with 1000 patients treated with cefetamet pivoxil. Current Medical Research and Opinion. 11(7). 442–452. 9 indexed citations
20.
Feist, Henning, et al.. (1981). Trial of ceftazidime efficacy in respiratory infections at two dose levels. Journal of Antimicrobial Chemotherapy. 8(suppl B). 299–301. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Powel Kazanjian Breakdown of academic impact, for papers by Renato Maserati Breakdown of academic impact, for papers by Sylvie Abel Breakdown of academic impact, for papers by William P. Bradley Breakdown of academic impact, for papers by Raquel Martínez Breakdown of academic impact, for papers by Henry C. Mwandumba Breakdown of academic impact, for papers by Vanni Borghi Breakdown of academic impact, for papers by Örjan Strannegård Breakdown of academic impact, for papers by Christophe Michon Breakdown of academic impact, for papers by Allan R. Tenorio
Rankless by CCL
2026